|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Contraception and dyslipidemia. |
| Knopp RH; LaRosa JC; Burkman RT Jr |
| AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY. 1993 Jun;168(6 Pt |
| The risks of cardiovascular disease associated with dyslipidemia differ in women and men, being more strongly |
| associated with triglyceride/high-density lipoprotein in middle-aged women than in men. Although the incidence of |
| heart disease is lower in women because they live longer, over a lifetime, cardiovascular disease in women is equal |
| to that in men, with the greatest incidence after 65 years of age. Major coronary events are rare among reproductive |
| age women who use oral contraceptives (OCs) and are related to the concomitant effects of age, smoking, diabetes, |
| hypertension, and obesity. Low estrogen-progestin dose OCs do not appear to promote cardiovascular disease and |
| can be used in women with controlled cholesterol elevations. Alternative contraceptive measures should be |
| considered for patients with severe uncontrolled hypercholesterolemia or a lipid disorder that carries a high risk of |
| coronary heart disease. In these conditions, thrombotic propensity associated with supraphysiologic doses of |
| estrogen in OCs might accelerate coronary thrombosis should an arteriosclerotic plaque rupture. Treatment of |
| hypercholesterolemia should follow the guidelines of the National Cholesterol Education Program and emphasize |
| hygienic measures. Contraceptive selection in hyperlipidemic patients should reflect a balance between the risk-- |
| and their management--of developing cardiovascular disease vs. the risk of pregnancy. (PubHealth.info Document ID: |
| PubHealth.info NOTE: The author(s) of this article titled, "Contraception and dyslipidemia.", is(are) Knopp RH; |
| LaRosa JC; Burkman RT Jr. The source of this article is "AMERICAN JOURNAL OF OBSTETRICS AND |
| GYNECOLOGY. 1993 Jun;168(6 Pt 2):1994-2005.". This article was published in 1993 in English language(s). |
| (PubHealth.info® Document ID: CONT2T 4534-06. All rights reserved with PubHealth.info) PIN: 9534 |
| This article is peer-reviewed. |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |